Comprehensive study provides new understandings of genomic influences on neuropsychiatric disease

FHS
May 24, 2024
3:30 am

A new analysis has revealed detailed information about genetic variation in brain cells that could open new avenues for the targeted treatment of diseases such as schizophrenia and Alzheimer’s disease.

FDA denies approval for Theratechnologies’ tesamorelin F8

Share this article EGRIFTA SV is approved for reducing excess abdominal fat in adult patients with human immunodeficiency virus (HIV) infection and lipodystrophy. Credit: Andrey_Popov/Shutterstock.com.

January 25, 2024

New study reveals global risk distribution of visceral leishmaniasis

Announcing a new article publication for Zoonoses journal. Visceral leishmaniasis (VL) is a vector-borne disease posing increasing public health concerns.

April 29, 2024

Thermo Fisher expects lasting benefits to bill targeting Chinese service providers

Thermo Fisher said it will be a “long-term beneficiary” of biopharma customers localizing their supply chains, given most of its network is based in the

April 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.